Characterization of Piperacillin/Tazobactam-Resistant Klebsiella oxytoca Recovered from a Nosocomial Outbreak.

Characterization of Piperacillin/Tazobactam-Resistant Klebsiella oxytoca Recovered from a Nosocomial Outbreak.

We characterized 12 clinical isolates of Klebsiella oxytoca with the extended-spectrum β-lactamase (ESBL) phenotype (high minimum inhibitory concentration [MIC] values of ceftriaxone) recovered over 9 months at a university hospital in Japan. To determine the clonality of the isolates, we used pulse...

Full description

Bibliographic Details
Main Authors:	Ai Fujita, Kouji Kimura, Satoru Yokoyama, Wanchun Jin, Jun-Ichi Wachino, Keiko Yamada, Hiroyuki Suematsu, Yuka Yamagishi, Hiroshige Mikamo, Yoshichika Arakawa
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2015-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4634934?pdf=render

Similar Items

Risk factors of nosocomial infections caused by piperacillin-tazobactam resistant Pseudomonas aeruginosa
by: Đorđević Zorana, et al.
Published: (2013-01-01)

Mechanisms of Piperacillin/Tazobactam Nephrotoxicity: Piperacillin/Tazobactam-Induced Direct Tubular Damage in Mice
by: Jihyun Yang, et al.
Published: (2023-06-01)

Comparison of the Effectiveness of Piperacillin-Tazobactam and Carbapenems in Nosocomial Infections with Extended-Spectrum Beta-lactamase-Producing Escherichia coli and Klebsiella pneumoniae
by: Müge AYHAN, et al.
Published: (2020-12-01)

Piperacillin/tazobactam in modern clinical practice
by: Igor Bereznyakov
Published: (2022-05-01)

Piperacillin–tazobactam as alternative to carbapenems for ICU patients
by: Benoit Pilmis, et al.
Published: (2017-11-01)

Pragmatic Comparison of Piperacillin/Tazobactam versus Carbapenems in Treating Patients with Nosocomial Pneumonia Caused by Extended-Spectrum β-Lactamase-Producing <i>Klebsiella pneumoniae</i>
by: Lei Zha, et al.
Published: (2022-10-01)

Comparison of risk of acute kidney injury between patients receiving the combination of teicoplanin and piperacillin/tazobactam versus vancomycin and piperacillin/tazobactam
by: Chi-Hao Shao, et al.
Published: (2022-01-01)

Topical piperacillin/tazobactam for recalcitrant pseudomonas aeruginosa keratitiS
by: Chew, F.L.M., et al.
Published: (2010)

Evaluation of Strategies for Reducing Vancomycin-Piperacillin/Tazobactam Incompatibility
by: Anthony Martin Mena, et al.
Published: (2023-08-01)

Piperacillin/Tazobactam-Induced Neutropenia: A Case Report
by: Hayati DEMİRASLAN, et al.
Published: (2012-03-01)

Piperacilina/tazobactam en el sistema VITEK ®2 Piperacillin / Tazobactam in the VITEk ®2 System
by: Javier Gutman, et al.
Published: (2011-06-01)

Hematologic Adverse Effects of Prolonged Piperacillin- Tazobactam Use in Adults
by: Aysun Benli, et al.
Published: (2018-11-01)

<i>Enterobacter </i>endophthalmitis: Treatment with intravitreal tazobactam- piperacillin
by: Singh Trehan, et al.
Published: (2007-01-01)

Results of the effectiveness of two piperacillin–tazobactam molecules in the real world
by: Jorge Enrique Machado-Alba, et al.
Published: (2018-11-01)

Impact of extended-infusion piperacillin-tazobactam in a Canadian community hospital
by: April J. Chan, et al.
Published: (2023-03-01)

Incidence and Determinants of Piperacillin/Tazobactam-Associated Hypokalemia: A Retrospective Study
by: Heenam Seo, et al.
Published: (2022-08-01)

Comparison of Cefepime with Piperacillin/Tazobactam Treatment in Patients with Hospital-Acquired Pneumonia
by: Bo-Guen Kim, et al.
Published: (2023-05-01)

Comparison of Piperacillin and Tazobactam Pharmacokinetics in Critically Ill Patients with Trauma or with Burn
by: Daniel J. Selig, et al.
Published: (2022-05-01)

Simple HPLC-UV Method for Piperacillin/Tazobactam Assay in Human Plasma
by: Khaled Abdelkawy, et al.
Published: (2023-02-01)

The impact of a best practice advisory on inpatient prescribing of piperacillin-tazobactam
by: Katherine L. Peterson, et al.
Published: (2022-01-01)

Galactomannan detection from piperacillin-tazobactam brands available in the Brazilian market
by: Melissa Orzechowski Xavier, et al.

Impact on Bacterial Resistance of Therapeutically Nonequivalent Generics: The Case of Piperacillin-Tazobactam.
by: Carlos A Rodriguez, et al.
Published: (2016-01-01)

An infant with Klebsiella oxytoca septic arthritis
by: Olof Hertting
Published: (2018-02-01)

Sulfamoyl Heteroarylcarboxylic Acids as Promising Metallo-β-Lactamase Inhibitors for Controlling Bacterial Carbapenem Resistance
by: Jun-ichi Wachino, et al.
Published: (2020-04-01)

Evaluation of Piperacillin/Sulbactam, Piperacillin/Tazobactam and Cefoperazone/Sulbactam Dosages in Gram-Negative Bacterial Bloodstream Infections by Monte Carlo Simulation
by: Xueting Wang, et al.
Published: (2023-02-01)

Analysis of IV Drugs in the Hospital Workflow by Raman Spectroscopy: The Case of Piperacillin and Tazobactam
by: Ioanna Chrisikou, et al.
Published: (2021-09-01)

A Case of DRESS Syndrome Associated with Piperacillin-Tazobactam Treatment and Literature Review
by: Seven ULUDOKUMACI, et al.
Published: (2012-12-01)

Acute kidney injury in villous cancer patients treated with vancomycin and tazobactam/piperacillin
by: Kaori Nakatani, et al.
Published: (2022-08-01)

Synthesis and evaluation of polymeric micelle containing piperacillin/tazobactam for enhanced antibacterial activity
by: Milani Morteza, et al.
Published: (2019-01-01)

Isolation and characterization of an SDS-degrading Klebsiella oxytoca.
by: Abd. Shukor, Mohd. Yunus, et al.
Published: (2009)

Comparison of piperacillin plasma concentrations in a prospective randomised trial of extended infusion versus intermittent bolus of piperacillin/tazobactam in paediatric patients
by: Tatchanapong Chongcharoenyanon, et al.
Published: (2021-07-01)

Hydroxyhexylitaconic acids as potent IMP-type metallo-β-lactamase inhibitors for controlling carbapenem resistance in Enterobacterales
by: Jun-ichi Wachino, et al.
Published: (2024-03-01)

Linear IgA dermatosis secondary to treatment with piperacillin-tazobactam in a nonagenarian patient
by: Vanesa García-Paz, et al.
Published: (2024-01-01)

Piperacillin–Tazobactam as an Adjuvant in the Mechanical Treatment of Patients with Periodontitis: A Randomized Clinical Study
by: Dolores Hurtado-Celotti, et al.
Published: (2022-11-01)

Electrolyte Disorders Associated with Piperacillin/Tazobactam: A Pharmacovigilance Study Using the FAERS Database
by: Heenam Seo, et al.
Published: (2023-01-01)

The effect of meropenem versus piperacillin-tazobactam in critically ill patients with sepsis and septic shock
by: Yang Sun, et al.
Published: (2023-06-01)

Cross-reactivity between piperacillin–tazobactam and cefoperazone–sulbactam in drug-induced immune thrombocytopenia
by: Xiaoyan He, et al.
Published: (2023-03-01)

Prevalence of Piperacillin-Tazobactam induced Hypersensitivity Reaction in Workers of Stallion’s Pharmaceutical Factory at Lahore
by: Anwar Ali Sulehri, et al.
Published: (2022-11-01)

Continuous infusion of piperacillin‐tazobactam significantly improves target attainment in children with cancer and fever
by: Sabine F. Maarbjerg, et al.
Published: (2022-10-01)

Outpatient therapy with piperacillin/tazobactam using elastomeric pumps in patients with Pseudomonas aeruginosa infection
by: Jose Luis Lamas Ferreiro, et al.
Published: (2021-04-01)